Valuation
- Market cap
- 4,043,000
- Revenue TTM
- $12,450,000
- Net income TTM
- $-7,490,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -60.16%
- Debt to equity
- -0.03
Trading
- Volume
- 300
- Avg volume
- 156,970
- Day's range
- $0.06 – $0.06
- Shares out
- 70,188,000
- Stochastic %K
- 68%
- Beta
- 9.73
- Analysts
- Strong Buy
- Price target
- $4.00
Company profile
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a...
Show more
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 310 214 0065
- Website
- https://www.emmausmedical.com
- Address
- 21250 Hawthorne Boulevard, Suite 800, Torrance, United States
Latest news
No headlines yet.
